SCHEMBL24596246

SCHEMBL24596246

CCOc1ccc(Br)c(F)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
MAPT P10636 1/20 0.40
BTK Q06187 1/20 0.36
MAPK8 P45983 1/20 0.36
HTT P42858 2/20 0.35
ADORA1 P30542 2/20 0.35
HPGD P15428 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP19A1 P11511 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PI4KA P42356 1/20 0.33
PIK3CG P48736 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
MBOAT4 Q96T53 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370695 0.80 NUDT1 (0.47) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9931250 0.78 HPGD (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL16783076 0.78 BTK (0.37) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL19155793 0.78 MAPT (0.37) MAPTBTKMAPK8HTTADORA1
SCHEMBL23414825 0.78 L3MBTL1 (0.45) MAPTSMN1; SMN2L3MBTL1MAPK1
SCHEMBL31541706 0.78 POLB (0.36) GABRG2GABRB3GABRA5GABRA3MAPT
SCHEMBL15908313 0.77 MAPT (0.40) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL10187309 0.77 ALDH1A1 (0.39) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL17593270 0.77 BTK (0.36) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL19250105 0.77 MAPT (0.36) MAPTBTKMAPK8HTTADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A GABRA1 1329/4885GABRG2 903/4885GABRB3 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.